Literature DB >> 20101683

X chromosome inactivation does not define the development of premature ovarian failure in fragile X premutation carriers.

Marian A Spath1, Willy N Nillesen, Arie P T Smits, Ton B Feuth, Didi D M Braat, Ad Geurts van Kessel, Helger G Yntema.   

Abstract

Since only 20% of female fragile X premutation carriers develop premature ovarian failure (POF, i.e., amenorrhea before age of 40 years), and since X chromosome inactivation (XCI) determines the phenotypic severity of full mutation women, we reasoned that the development of POF in fragile X premutation carriers could be due to skewed XCI (XCI ratio >80:20). To determine inactivation ratios and activities of the premutations, inactivation patterns were assessed in peripheral blood samples from 101 fragile X premutation carriers (mean age 47.1 years, range 12-72) through analysis of the AR and FMR1 loci, respectively. In addition, AR inactivation patterns were assessed in peripheral blood samples from 25 women with idiopathic POF (mean age 31.7 years, range 19-48). We addressed the association between age and skewed XCI because older women are prone to XCI skewness. The median XCI ratios were 68% for premutation carriers with POF (N = 37), 67% for premutation carriers without POF (N = 64) and 61% for women with idiopathic POF (N = 25). The incidence of skewing was similar in all groups, that is, 7 of 37 (18.9%) in premutation carriers with POF, 11 of 64 (17.2%) in premutation carriers without POF, and 3 of 25 (12%) in women with idiopathic POF. There was good concordance between inactivation ratios at the two loci tested in 62 premutation carriers (intraclass correlation coefficient = 0.86; P < 0.01). No age-specific skewing was observed. Skewed XCI and activity of the premutation are not associated with POF in fragile X premutation carriers. Copyright 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20101683     DOI: 10.1002/ajmg.a.33243

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  12 in total

1.  Characterization and genetic diagnosis of centronuclear myopathies in seven Chinese patients.

Authors:  Yan Zhao; Zhe Zhao; Hongrui Shen; Qi Bing; Jing Hu
Journal:  Neurol Sci       Date:  2018-09-19       Impact factor: 3.307

2.  Ovarian abnormalities in a mouse model of fragile X primary ovarian insufficiency.

Authors:  Gloria E Hoffman; Wei Wei Le; Ali Entezam; Noriyuki Otsuka; Zhi-Bin Tong; Lawrence Nelson; Jodi A Flaws; John H McDonald; Sanjeeda Jafar; Karen Usdin
Journal:  J Histochem Cytochem       Date:  2012-04-02       Impact factor: 2.479

3.  Pathogenic Variants in GPC4 Cause Keipert Syndrome.

Authors:  David J Amor; Sarah E M Stephenson; Mirna Mustapha; Martin A Mensah; Charlotte W Ockeloen; Wei Shern Lee; Rick M Tankard; Dean G Phelan; Marwan Shinawi; Arjan P M de Brouwer; Rolph Pfundt; Cari Dowling; Tomi L Toler; V Reid Sutton; Emanuele Agolini; Martina Rinelli; Rossella Capolino; Diego Martinelli; Giuseppe Zampino; Miroslav Dumić; William Reardon; Charles Shaw-Smith; Richard J Leventer; Martin B Delatycki; Tjitske Kleefstra; Stefan Mundlos; Geert Mortier; Melanie Bahlo; Nicola J Allen; Paul J Lockhart
Journal:  Am J Hum Genet       Date:  2019-04-11       Impact factor: 11.025

4.  Mutations in MED12 cause X-linked Ohdo syndrome.

Authors:  Anneke T Vulto-van Silfhout; Bert B A de Vries; Bregje W M van Bon; Alexander Hoischen; Martina Ruiterkamp-Versteeg; Christian Gilissen; Fangjian Gao; Marloes van Zwam; Cornelis L Harteveld; Anthonie J van Essen; Ben C J Hamel; Tjitske Kleefstra; Michèl A A P Willemsen; Helger G Yntema; Hans van Bokhoven; Han G Brunner; Thomas G Boyer; Arjan P M de Brouwer
Journal:  Am J Hum Genet       Date:  2013-02-07       Impact factor: 11.025

Review 5.  Genetics of primary ovarian insufficiency: new developments and opportunities.

Authors:  Yingying Qin; Xue Jiao; Joe Leigh Simpson; Zi-Jiang Chen
Journal:  Hum Reprod Update       Date:  2015-08-04       Impact factor: 15.610

6.  A novel methylation PCR that offers standardized determination of FMR1 methylation and CGG repeat length without southern blot analysis.

Authors:  Marina Grasso; Elles M J Boon; Stela Filipovic-Sadic; Patrick A van Bunderen; Elena Gennaro; Ru Cao; Gary J Latham; Andrew G Hadd; Domenico A Coviello
Journal:  J Mol Diagn       Date:  2013-10-29       Impact factor: 5.568

7.  Approaches to identify genetic variants that influence the risk for onset of fragile X-associated primary ovarian insufficiency (FXPOI): a preliminary study.

Authors:  Emily G Allen; Wendy E Grus; Sarayu Narayan; Whitney Espinel; Stephanie L Sherman
Journal:  Front Genet       Date:  2014-08-07       Impact factor: 4.599

Review 8.  Use of model systems to understand the etiology of fragile X-associated primary ovarian insufficiency (FXPOI).

Authors:  Stephanie L Sherman; Eliza C Curnow; Charles A Easley; Peng Jin; Renate K Hukema; Maria Isabel Tejada; Rob Willemsen; Karen Usdin
Journal:  J Neurodev Disord       Date:  2014-08-13       Impact factor: 4.025

9.  Endocrine Dysfunction in Female FMR1 Premutation Carriers: Characteristics and Association with Ill Health.

Authors:  Sonya Campbell; Sarah E A Eley; Andrew G McKechanie; Andrew C Stanfield
Journal:  Genes (Basel)       Date:  2016-11-18       Impact factor: 4.096

Review 10.  Molecular Correlates and Recent Advancements in the Diagnosis and Screening of FMR1-Related Disorders.

Authors:  Indhu-Shree Rajan-Babu; Samuel S Chong
Journal:  Genes (Basel)       Date:  2016-10-14       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.